The file was originally located at but has been removed.
  • They've finally admitted it, albeit to their investors and not us diabetics!

"EMEA approves NovoRapid™ - a new rapid-acting insulin analogue

9 September 1999

Novo Nordisk (NYSE: NVO) today announced that the European Medicines Evaluation Agency (EMEA) approved NovoRapid™  (insulin aspart), the company’s new rapid-acting insulin analogue, for the treatment of diabetes.

In long-term, large-scale clinical trials, NovoRapid™ significantly improved glycemic control compared to that of soluble human insulin and significantly reduced the risk of major nocturnal hypoglycemia.

  • Historically, improving glycemic control with soluble human insulin has been associated with an increased risk of hypoglycemia."

Contact us: 

Return to Top of Page